Breast cancer drug, Femara, was submitted for additional regulatory approval by the US Food and Drug Administration today from Swiss pharmaceutical company Novartis. Femara presents the hope of post-surgery medication that helps older women fight tumors.
Comments (0)
Please sign in to leave a comment.
No comments yet. Be the first to comment!